May 21, 2026 · Last updated: May 21, 2026
Retatrutide Hits 30.3% Average Weight Loss in TRIUMPH-1 Phase 3 Trial
TL;DR
Eli Lilly announced positive topline results from TRIUMPH-1, the pivotal Phase 3 trial of retatrutide, an investigational first-in-class triple hormone receptor agonist. At 80 weeks, the 12 mg dose produced average weight loss of 28.3% (70.3 lbs). In an extension among participants with BMI ≥35, the same dose produced 30.3% average weight loss (85 lbs) at 104 weeks — a result Lilly compared to bariatric surgery outcomes. Analysts now project a 2027 FDA approval decision.
What is retatrutide?
Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. Unlike single-agonist drugs like semaglutide (GLP-1 only) or dual-agonist drugs like tirzepatide (GIP + GLP-1), retatrutide’s third receptor target — glucagon — drives additional fat metabolism and energy expenditure on top of appetite suppression and improved glucose handling.
TRIUMPH-1 study design
TRIUMPH-1 enrolled 2,339 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity. Participants without diabetes received once-weekly injections of retatrutide at 4 mg, 9 mg, or 12 mg, or placebo. The primary phase ran 80 weeks. A pre-specified blinded extension continued select participants with baseline BMI ≥35 through 104 weeks.
80-week primary results
Mean weight loss versus baseline:
- 12 mg dose: 28.3% (70.3 lbs)
- 9 mg dose: 25.9% (64.4 lbs)
- 4 mg dose: 19.0% (47.2 lbs)
- Placebo: 2.2% (5.5 lbs)
In the 12 mg group, 45.3% of participants lost at least 30% of their body weight — a threshold long associated with bariatric surgery rather than pharmaceutical intervention. Additionally, 65.3% of participants in the 12 mg group reached a BMI below 30, dropping under the clinical obesity threshold by week 80. Among participants who started with class 3 obesity (BMI ≥40), 37.5% reached a BMI below 30 by the end of the primary phase.
104-week extension results
The pre-specified extension continued participants with baseline BMI ≥35 on the 12 mg dose through week 104. Average weight loss climbed to 30.3% (85.0 lbs). The curve had not yet plateaued at study end, suggesting additional weight loss would have continued with longer follow-up.
How retatrutide compares to current GLP-1 leaders
In benchmark Phase 3 trials, semaglutide (marketed as Wegovy and Ozempic) produced approximately 15-17% weight loss over comparable durations, and tirzepatide (marketed as Zepbound and Mounjaro) produced approximately 21-25%. Retatrutide’s 28.3% at 80 weeks — and 30.3% at 104 weeks — positions the triple agonist as the most effective weight-loss pharmaceutical in late-stage development. BMO Capital Markets called the profile “supremely strong” in a Thursday research note. Truist Securities described the numbers as “a new benchmark for anti-obesity medications.”
Cardiometabolic benefits beyond weight loss
TRIUMPH-1 reported significant improvements from baseline across multiple cardiovascular risk markers in retatrutide-treated participants:
- Waist circumference
- Non-HDL cholesterol
- Triglycerides
- Systolic blood pressure
- High-sensitivity C-reactive protein (hsCRP)
These secondary endpoints suggest retatrutide’s benefits extend beyond body weight to broader cardiometabolic health — consistent with mechanism-based expectations from the triple-agonist receptor profile.
Safety and tolerability
The safety profile mirrored earlier-phase data. Gastrointestinal events (nausea, vomiting, diarrhea) were the most common adverse events and more frequent than placebo. Some sensory and urinary events also occurred more frequently than placebo.
Discontinuation rates due to adverse events were dose-dependent:
- 4 mg: 4.1%
- 9 mg: 12.2%
- 12 mg: 18.2%
- Placebo: 4.0%
Notably, the 4 mg dose — reached with only a single dose escalation step — achieved 19.0% weight loss with discontinuation rates comparable to placebo. This likely positions 4 mg as the entry-level option for patients prioritizing tolerability over maximum efficacy.
What’s next
Lilly has seven additional Phase 3 readouts expected through 2026, covering retatrutide across obesity, type 2 diabetes, and osteoarthritis populations. TRIUMPH-4 reported in December 2025, showing 28.7% weight loss plus substantial knee osteoarthritis pain relief in patients with both conditions.
Analysts project an FDA approval decision in 2027, with retatrutide expected to launch as Lilly’s flagship next-generation obesity therapy. Full TRIUMPH-1 results will be presented at a future medical conference and published in a peer-reviewed journal.
Implications for the research peptide community
Retatrutide remains an investigational compound — not approved for human therapeutic use anywhere in the world as of this writing. Within the research peptide community, retatrutide has been available from third-party vendors for several years preceding Lilly’s anticipated commercial launch. The TRIUMPH-1 data formally validates the triple-agonist mechanism as a meaningful step beyond single and dual GLP-1 receptor agonism, and confirms the compound’s place alongside semaglutide and tirzepatide as one of the three pivotal compounds in this rapidly evolving therapeutic space.
Sources
This article is for informational and educational purposes only and does not constitute medical advice. Retatrutide remains an investigational compound under active Phase 3 evaluation and is not FDA-approved for any indication. All research compounds referenced are for laboratory use only.
Have a question about Retatrutide Hits 30.3% Average Weight Loss in TRIUMPH-1 Phase 3 Trial? Send us an email →